About: Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review)
Creator	Moschos, Sterghios Nitulescu, George Spandidos, A Tsatsakis, Aristidis Drakoulis, Nikolaos Mihai Nitulescu, George Nicolae Daniel Ion, George Nikolouzakis, Taxiarchis Nitulescu, Georgiana Paunescu, Horia
Source	Medline; PMC; WHO
abstract	The major impact produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) focused many researchers attention to find treatments that can suppress transmission or ameliorate the disease. Despite the very fast and large flow of scientific data on possible treatment solutions, none have yet demonstrated unequivocal clinical utility against coronavirus disease 2019 (COVID-19). This work represents an exhaustive and critical review of all available data on potential treatments for COVID-19, highlighting their mechanistic characteristics and the strategy development rationale. Drug repurposing, also known as drug repositioning, and target based methods are the most used strategies to advance therapeutic solutions into clinical practice. Current in silico, in vitro and in vivo evidence regarding proposed treatments are summarized providing strong support for future research efforts.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.3892/ijmm.2020.4608
bibo:pmid	32468014
has license	cc-by-nc-nd
sha1sum (hex)	bee57fc1cc574d9c8bb84da8af78789a75e32012
schema:url	https://doi.org/10.3892/ijmm.2020.4608
resource representing a document's title	Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review)
has PubMed Central identifier	PMC7307820
has PubMed identifier	32468014
schema:publication	Int J Mol Med
resource representing a document's body	covid:bee57fc1cc574d9c8bb84da8af78789a75e32012#body_text
is schema:about of	named entity 'critical review' named entity 'infection' named entity 'DISEASE' named entity 'MAJOR' named entity 'FLOW' named entity 'KNOWN' named entity 'SCIENTIFIC DATA' named entity 'THEIR' named entity 'WORK' named entity 'CRITICAL REVIEW' named entity 'STRATEGY' named entity 'DEVELOPMENT' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2' named entity 'exhaustive' named entity 'large' named entity 'focused' named entity 'coronavirus disease 2019' named entity 'future' named entity 'coronavirus disease 2019' named entity 'cOVId-19' named entity 'SARS-CoV-2' named entity 'Niclosamide' named entity 'HCV' named entity 'antivirals' named entity 'infection' named entity 'SARS-CoV-2' named entity 'clinical trials' named entity 'prodrug' named entity 'SARS-coV-2' named entity 'caco-2 cells' named entity 'urokinase' named entity 'SARS' named entity 'alkaloid' named entity 'GS-441524' named entity 'enterocytes' named entity 'filoviruses' named entity 'SARS-coV-2' named entity 'teratogenicity' named entity 'shRNA' named entity 'IFN-β' named entity 'receptor' named entity 'antiviral' named entity 'SARS-coV-2' named entity 'ruxolitinib' named entity 'cytosolic' named entity 'SARS-CoV' named entity 'SARS-coV-2' named entity 'human coronaviruses' named entity 'administered intravenously' named entity 'SARS-CoV' named entity 'nucleocapsid' named entity 'experimental models' named entity 'bunyaviruses' named entity 'clinical trials' named entity 'antisense' named entity 'SARS' named entity 'tizoxanide' named entity 'cOVId-19' named entity 'Akt' named entity 'RT-PCR' named entity 'Immunosuppressants' named entity 'antisense' named entity 'elevated liver enzymes' named entity 'RT-PcR' named entity 'favipiravir' named entity 'Janus kinase (JAK) inhibitors' named entity 'broad-spectrum antibiotics' named entity 'supportive treatment' named entity 'auto-immune diseases' named entity 'remdesivir' named entity 'Ivermectin' named entity 'anti-inflammatory'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software